QUANTUM X LABS INC. quarterly report, Q2 FY2015

Filing summary

The supplied filing is Zaxis International Inc.’s Form 10-Q for the quarter ended June 30, 2015, not a filing identified as Quantum X Labs Inc. The company describes itself as a former shell with no operating business or revenue during the reported periods. It was pursuing a reverse merger with Emerald Medical Applications Ltd., a developer of skin-imaging and melanoma-detection technology.

Financial results and liquidity

MetricThree months ended June 30, 2015Six months ended June 30, 2015Comparable 2014 period
Revenue$0$0$0
Operating expenses$388,390$622,326$6,500 and $16,928, respectively
Net loss$390,606$627,553$6,807 and $16,928, respectively
Basic and diluted loss per share$0.08$0.13$0.00 and $0.01, respectively
Cash at period end$467,380$1,000 at December 31, 2014
Liabilities at period end$0 reported$186,159 at December 31, 2014
Cash used in operations$666,245 for the six months$7,750 for the six months
Cash provided by financing$1,132,625 for the six months$7,750 for the six months

The company reported no revenue or gross margin. General and administrative expense rose to $88,390 for the quarter and $132,326 for the six months, which management attributed mainly to merger-related costs. Other expense of $300,000 for the quarter and $490,000 for the six months related to advances to Emerald that were expensed because collectability was not considered reasonably assured. The filing reports $4,699 of six-month interest expense.

Financing cash flow included $1,185,000 of net proceeds from unit sales, offset by $52,375 of debt repayments. The company reported $467,380 in cash and no liabilities at June 30. The balance sheet shows total assets and stockholders’ equity of $467,380, including $385,000 in stock payable. The units sold for $0.40 each included one common share and a two-year warrant exercisable at $0.80.

Changes, outlook, and risks

  • Losses increased substantially from 2014, primarily reflecting the Emerald advances and merger-related expenses.
  • Management said the definitive reverse-merger agreement closed on July 14, 2015, after quarter-end, and Emerald became a wholly owned subsidiary. The filing describes Emerald’s DermaCompare software and planned sales to healthcare providers and related channels, but gives no revenue guidance or quantified operating forecast.
  • The company sold $1,185,000 of units during the first half of 2015. Shares associated with unit sales were to be issued after completion of the reverse merger. The company also reported a reverse stock split and an increase in authorized common shares to 490 million.
  • The filing warns of substantial doubt about the company’s ability to continue as a going concern: it had no revenue, recurring losses, negative operating cash flow, and limited resources. Management said additional financing was necessary and believed equity-financing efforts could support continued operations. Repayment of the Emerald advances was described as highly uncertain if the merger did not close.
  • Management concluded disclosure controls and procedures were not effective as of June 30, 2015. No material changes to internal control over financial reporting were reported during the quarter.
  • The filing reports no legal proceedings and no defaults upon senior securities. It refers investors to the August 5, 2015 Form S-1 for risk factors.

Important facts to verify

  • Confirm the issuer and filing identity: the document names Zaxis International Inc., while the request names Quantum X Labs Inc.
  • Reconcile numerical inconsistencies: the cash-flow statement gives six-month net loss as $627,533, while the operations statement and MD&A report $627,553. The filing also varies in describing the debt-settlement item as a gain or loss.
  • Review the $490,000 of advances to Emerald, the company’s collectability assessment, and whether the merger changed the treatment or recoverability of those advances.
  • Verify the post-quarter merger closing, resulting ownership and dilution, and the August 5 registration statement’s proposed resale of 19,361,758 shares.
  • Clarify the filing’s going-concern and liquidity statements against its June 30 balance sheet, which reports positive cash and no liabilities, and its separate assertion of negative working capital.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.